ClinicalTrials.gg
TerminatedNCT06681766Updated Jul 10, 2026

A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia

A Phase 1 interventional study of Nomlabofusp and Placebo in Friedreich Ataxia, sponsored by Larimar Therapeutics, Inc.. Terminated at 1 site in United States. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Larimar Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Review of Cohort 1 data facilitated direct enrollment into open label study and eliminate pause in study drug administration between PK study and open label study.

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Friedreich Ataxia with a site in United States — 18 open to participants now, 25 under way, 4 of them phase 3. Friedreich Ataxia · United States.

Enrollment
37th of 49
18 · median 32
Started
2024
with 6 others
Phase 1
15 of 71
4 open now
Registered
60th of 71
by date
Lead sponsor
8 of 71
Larimar Therapeutics, Inc.

Among the 71 studies in Friedreich Ataxia with a site in United States, this one is the 37th largest by enrollment of the 49 interventional ones that give a count, is one of 7 that started in 2024, is one of 15 in phase 1, and was the 60th registered.

Friedreich Ataxia

111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.

Browse Friedreich Ataxia studies →

Open to participants now

18 of the 71 studies in Friedreich Ataxia with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Friedreich Ataxia with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety and tolerability of nomlabofusp (CTI-1601) in adolescents and children with Friedreich's ataxia (FRDA).

Read the detailed description

This is a randomized, double-blind, placebo-controlled study evaluating a weight-based dose of nomlabofusp versus placebo in adolescents and children with FRDA. The study will consist of at least two cohorts with at least 12 to 15 participants in each cohort. Participants will be dosed once daily (QD) for 7 days.

03

Conditions studied

  • Friedreich Ataxia

Browse trials for

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has genetically confirmed diagnosis of FRDA manifested by homozygous GAA repeat expansions, with repeat sizing (if available) included on the diagnosis report.
  2. Male or female subjects ≥ 2 to \< 18 years of age at screening.
  3. Subjects must weigh ≥ 10.0 kg.
  4. Subject must be able to traverse a distance of 25 feet with or without some assistive device (e.g., cane, walker, crutches, self-propelled wheelchair) and meet the following requirements:

    1. Be able to sit upright with thighs together and arms crossed without requiring support on more than 2 sides;
    2. Be able to transfer from bed to chair independently or with assistance if, in the opinion of the investigator, the degree of physical disability does not result in undue risk to the subject while participating in the study; and
    3. Perform basic age-appropriate daily care, such as feeding themselves and personal hygiene, with minimal assistance.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who are confirmed as compound heterozygous (GAA repeat expansion on only 1 allele) for FRDA.
  2. Subject has any condition, disease, or situation, including a cardiac condition or disease, that in the opinion of the investigator could confound the results of the study or put the subject at undue risk, making participation inadvisable.
  3. Subjects currently receiving or having received omaveloxolone within 30 days prior to Screening.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Nomlabofusp

    Subcutaneous injection of 0.8 mg/kg, with a maximum dose of 50 mg, once daily for 7 days

    Drug: Nomlabofusp

  • Placebo comparator
    Placebo

    Subcutaneous injection once daily for 7 days

    Drug: Placebo

Interventions

  • Nomlabofusp is a recombinant fusion protein provided in a sterile, preservative-free buffered solution for subcutaneous injection intended to deliver human frataxin, the protein deficient in Friedreich's ataxia.

    Also known as: CTI-1601

  • DrugPlacebo

    The placebo is a sterile, preservative-free, clear liquid for subcutaneous injection.

    Also known as: CTI-1601 Placebo, Nomlabofusp Placebo

06

What researchers measure

Primary outcomes

  1. Number of AEs, TEAEs, related TEAEs, Grade 3/4 TEAEs, and SAEs

    Number

    Time frame: Up to 72 days (including screening)

  2. Number of subjects with ISRs

    Number

    Time frame: Up to 37 days

  3. Change from baseline in electrocardiogram (ECG) parameter - heart rate (HR)

    Number

    Time frame: Baseline, Day 7

  4. Change from baseline in electrocardiogram (ECG) parameter - PR interval

    Number

    Time frame: Baseline, Day 7

  5. Change from baseline in electrocardiogram (ECG) parameter - QRS complex

    Number

    Time frame: Baseline, Day 7

  6. Change from baseline in electrocardiogram (ECG) parameter - QT interval

    Number

    Time frame: Baseline, Day 7

  7. Change from baseline in electrocardiogram (ECG) parameter - QTcF (Corrected QT Interval)

    Number

    Time frame: Baseline, Day 7

  8. Change from baseline in echocardiogram (ECHO) parameter - ejection fraction (EF)

    Number

    Time frame: Baseline, Day 7

  9. Change from baseline in echocardiogram (ECHO) parameter - left ventricular end-diastolic volume (LV EDV)

    Number

    Time frame: Baseline, Day 7

  10. Change from baseline in echocardiogram (ECHO) parameter - left ventricular end-systolic volume (LV ESV)

    Number

    Time frame: Baseline, Day 7

  11. Change from baseline in echocardiogram (ECHO) parameter - relative wall thickness (RWT)

    Number

    Time frame: Baseline, Day 7

  12. Change from baseline in echocardiogram (ECHO) parameter - left ventricular mass (LVM)

    Number

    Time frame: Baseline, Day 7

  13. Change from baseline in echocardiogram (ECHO) parameter - left ventricular posterior wall thickness

    Number

    Time frame: Baseline, Day 7

  14. Change from baseline in echocardiogram (ECHO) parameter - septal wall thickness

    Number

    Time frame: Baseline, Day 7

  15. Change from baseline in echocardiogram (ECHO) parameter - mitral valve inflow Doppler

    Number

    Time frame: Baseline, Day 7

  16. Change from baseline in echocardiogram (ECHO) parameter - tissue Doppler

    Number

    Time frame: Baseline, Day 7

  17. Change from baseline in clinical laboratory assessment - sodium

    Number

    Time frame: Baseline, Day 7

  18. Change from baseline in clinical laboratory assessment - potassium

    Number

    Time frame: Baseline, Day 7

  19. Change from baseline in clinical laboratory assessment - glucose

    Number

    Time frame: Baseline, Day 7

  20. Change from baseline in clinical laboratory assessment - blood urea nitrogen

    Number

    Time frame: Baseline, Day 7

  21. Change from baseline in clinical laboratory assessment - creatinine

    Number

    Time frame: Baseline, Day 7

  22. Change from baseline in clinical laboratory assessment - calcium, chloride

    Number

    Time frame: Baseline, Day 7

  23. Change from baseline in clinical laboratory assessment - phosphorus

    Number

    Time frame: Baseline, Day 7

  24. Change from baseline in clinical laboratory assessment - total protein

    Number

    Time frame: Baseline, Day 7

  25. Change from baseline in clinical laboratory assessment - total CO2

    Number

    Time frame: Baseline, Day 7

  26. Change from baseline in clinical laboratory assessment - albumin

    Number

    Time frame: Baseline, Day 7

  27. Change from baseline in clinical laboratory assessment - AST

    Number

    Time frame: Baseline, Day 7

  28. Change from baseline in clinical laboratory assessment - ALT

    Number

    Time frame: Baseline, Day 7

  29. Change from baseline in clinical laboratory assessment - GGT

    Number

    Time frame: Baseline, Day 7

  30. Change from baseline in clinical laboratory assessment - ALP

    Number

    Time frame: Baseline, Day 7

  31. Change from baseline in clinical laboratory assessment - total bilirubin

    Number

    Time frame: Baseline, Day 7

  32. Change from baseline in clinical laboratory assessment - uric acid

    Number

    Time frame: Baseline, Day 7

  33. Change from baseline in clinical laboratory assessment - HbA1c

    Number

    Time frame: Baseline, Day 7

  34. Change from baseline in clinical laboratory assessment - hemoglobin

    Number

    Time frame: Baseline, Day 7

  35. Change from baseline in clinical laboratory assessment - hematocrit

    Number

    Time frame: Baseline, Day 7

  36. Change from baseline in clinical laboratory assessment - RBC count

    Number

    Time frame: Baseline, Day 7

  37. Change from baseline in clinical laboratory assessment - RDW

    Number

    Time frame: Baseline, Day 7

  38. Change from baseline in clinical laboratory assessment - MCV

    Number

    Time frame: Baseline, Day 7

  39. Change from baseline in clinical laboratory assessment - MCH

    Number

    Time frame: Baseline, Day 7

  40. Change from baseline in clinical laboratory assessment - platelet count

    Number

    Time frame: Baseline, Day 7

  41. Change from baseline in clinical laboratory assessment - WBC count

    Number

    Time frame: Baseline, Day 7

  42. Change from baseline in clinical laboratory assessment - ANC

    Number

    Time frame: Baseline, Day 7

  43. Change from baseline in clinical laboratory assessment - Eosinophils

    Number

    Time frame: Baseline, Day 7

  44. Change from baseline in clinical laboratory assessment - Monocytes

    Number

    Time frame: Baseline, Day 7

  45. Change from baseline in clinical laboratory assessment - Basophils

    Number

    Time frame: Baseline, Day 7

  46. Change from baseline in clinical laboratory assessment - Lymphocytes

    Number

    Time frame: Baseline, Day 7

  47. Change from baseline in clinical laboratory assessment - Bands

    Number

    Time frame: Baseline, Day 7

  48. Change from baseline in clinical laboratory assessment - Neutrophils

    Number

    Time frame: Baseline, Day 7

  49. Change from baseline in clinical laboratory assessment - Cholesterol

    Number

    Time frame: Baseline, Day 7

  50. Change from baseline in clinical laboratory assessment - HDL cholesterol

    Number

    Time frame: Baseline, Day 7

  51. Change from baseline in clinical laboratory assessment - LDL cholesterol

    Number

    Time frame: Baseline, Day 7

  52. Change from baseline in clinical laboratory assessment - Triglycerides

    Number

    Time frame: Baseline, Day 7

  53. Change from baseline in clinical laboratory assessment - very low-density lipoprotein cholesterol

    Number

    Time frame: Baseline, Day 7

  54. Change from baseline in clinical laboratory assessment - pH

    Number

    Time frame: Baseline, Day 7

  55. Change from baseline in clinical laboratory assessment - protein

    Number

    Time frame: Baseline, Day 7

  56. Change from baseline in clinical laboratory assessment - blood

    Number

    Time frame: Baseline, Day 7

  57. Change from baseline in clinical laboratory assessment - ketones

    Number

    Time frame: Baseline, Day 7

  58. Change from baseline in clinical laboratory assessment - bilirubin

    Number

    Time frame: Baseline, Day 7

  59. Change from baseline in clinical laboratory assessment - urobilinogen

    Number

    Time frame: Baseline, Day 7

  60. Change from baseline in clinical laboratory assessment - nitrites

    Number

    Time frame: Baseline, Day 7

  61. Change from baseline in clinical laboratory assessment - leukocyte esterase

    Number

    Time frame: Baseline, Day 7

  62. Change from baseline in clinical laboratory assessment - color

    Number

    Time frame: Baseline, Day 7

  63. Change from baseline in clinical laboratory assessment - specific gravity

    Number

    Time frame: Baseline, Day 7

  64. Change from baseline in pulse rate

    Number

    Time frame: Baseline, Day 7

  65. Number of subjects with abnormal physical examinations

    Number

    Time frame: Up to 72 days (including screening)

  66. Number of subjects with suicidal ideation, suicidal behavior, and suicidal ideation or behavior based on the Columbia Suicide Severity Rating Scale (C-SSRS)

    Number

    Time frame: Up to 72 days (including screening)

  67. Number of subjects who discontinue treatment and/or study

    Number

    Time frame: Up to 37 days

Secondary outcomes

  1. AUC0-last

    Area under the concentration-time-curve to the last quantifiable timepoint

    Time frame: Days 1, 7

  2. Cmax

    Maximum observed concentration

    Time frame: Days 1, 7

  3. Tmax

    Time of maximum observed concentration

    Time frame: Days 1, 7

  4. Ctrough

    Predose concentration

    Time frame: Days 1, 7

  5. Change from baseline in FXN concentrations normalized to total protein observed in buccal cells collected from cheek swabs

    Number

    Time frame: Baseline, Day 7

07

Study locations

1 site
  • Uncommon Cures
    Chevy Chase, Maryland 20815, United States
08

References and documents

Publications

  • Delatycki MB, Corben LA. Clinical features of Friedreich ataxia. J Child Neurol. 2012 Sep;27(9):1133-7. doi: 10.1177/0883073812448230. Epub 2012 Jun 29. PubMed 22752493 ↗
  • Deutsch EC, Santani AB, Perlman SL, Farmer JM, Stolle CA, Marusich MF, Lynch DR. A rapid, noninvasive immunoassay for frataxin: utility in assessment of Friedreich ataxia. Mol Genet Metab. 2010 Oct-Nov;101(2-3):238-45. doi: 10.1016/j.ymgme.2010.07.001. Epub 2010 Jul 8. PubMed 20675166 ↗
  • Fahey MC, Corben L, Collins V, Churchyard AJ, Delatycki MB. How is disease progress in Friedreich's ataxia best measured? A study of four rating scales. J Neurol Neurosurg Psychiatry. 2007 Apr;78(4):411-3. doi: 10.1136/jnnp.2006.096008. Epub 2006 Oct 20. PubMed 17056635 ↗
  • Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil. 1988 Oct;69(10):850-4. PubMed 3178453 ↗
  • Indelicato E, Nachbauer W, Eigentler A, Amprosi M, Matteucci Gothe R, Giunti P, Mariotti C, Arpa J, Durr A, Klopstock T, Schols L, Giordano I, Burk K, Pandolfo M, Didszdun C, Schulz JB, Boesch S; EFACTS (European Friedreich's Ataxia Consortium for Translational Studies). Onset features and time to diagnosis in Friedreich's Ataxia. Orphanet J Rare Dis. 2020 Aug 3;15(1):198. doi: 10.1186/s13023-020-01475-9. PubMed 32746884 ↗
  • Koeppen AH. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci. 2011 Apr 15;303(1-2):1-12. doi: 10.1016/j.jns.2011.01.010. PubMed 21315377 ↗
  • Lawerman TF, Brandsma R, Burger H, Burgerhof JGM, Sival DA; the Childhood Ataxia and Cerebellar Group of the European Pediatric Neurology Society. Age-related reference values for the pediatric Scale for Assessment and Rating of Ataxia: a multicentre study. Dev Med Child Neurol. 2017 Oct;59(10):1077-1082. doi: 10.1111/dmcn.13507. Epub 2017 Aug 17. PubMed 28815574 ↗
  • Lazaropoulos M, Dong Y, Clark E, Greeley NR, Seyer LA, Brigatti KW, Christie C, Perlman SL, Wilmot GR, Gomez CM, Mathews KD, Yoon G, Zesiewicz T, Hoyle C, Subramony SH, Brocht AF, Farmer JM, Wilson RB, Deutsch EC, Lynch DR. Frataxin levels in peripheral tissue in Friedreich ataxia. Ann Clin Transl Neurol. 2015 Aug;2(8):831-42. doi: 10.1002/acn3.225. Epub 2015 Jul 1. PubMed 26339677 ↗
  • Pandolfo M. Friedreich ataxia. Arch Neurol. 2008 Oct;65(10):1296-303. doi: 10.1001/archneur.65.10.1296. PubMed 18852343 ↗
  • Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Clinical outcomes assessment in multiple sclerosis. Ann Neurol. 1996 Sep;40(3):469-79. doi: 10.1002/ana.410400321. PubMed 8797541 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Apr 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2024
First posted
Nov 8, 2024
StartActual
Dec 6, 2024
Primary completionActual
Apr 27, 2025
CompletionActual
Apr 27, 2025
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06681766
Lead sponsor
Larimar Therapeutics, Inc.
Responsible party
Sponsor
First posted
Nov 8, 2024
Start date
Dec 6, 2024
Primary completion
Apr 27, 2025
Completion
Apr 27, 2025
Last update
Jul 10, 2026

Study contacts

Larimar Therapeutics, Inc.
study chair · Larimar Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nomlabofusp

Start the discussion